Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China · Delayed Price · Currency is CNY 3.230
-0.040 (-1.22%)
Oct 8, 2026, 3:04 PM CST
SHE:002589 Revenue
Realcan Pharmaceutical Group had revenue of 1.71B CNY in the quarter ending June 30, 2026, a decrease of -4.46%. This brings the company's revenue in the last twelve months to 7.17B, down -4.16% year-over-year. In the year 2025, Realcan Pharmaceutical Group had annual revenue of 7.30B, down -8.42%. That makes Realcan Pharmaceutical Group the 7,296th largest company in the world by revenue and 1,050th in China.
Revenue (ttm)
7.17B
Revenue Growth
-4.16%
P/S Ratio
0.67
Revenue / Employee
2.98M
Employees
2,407
Market Cap
4.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.30B | -670.67M | -8.42% |
| Dec 31, 2024 | 7.97B | -67.84M | -0.84% |
| Dec 31, 2023 | 8.03B | -4.28B | -34.74% |
| Jan 1, 2023 | 12.31B | -8.75B | -41.54% |
| Jan 1, 2022 | 21.06B | -6.17B | -22.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jointown Pharmaceutical Group | 167.56B |
| C.Q. Pharmaceutical Holding | 81.39B |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company | 77.91B |
| China National Accord Medicines Corporation | 72.89B |
| China National Medicines Corporation | 53.56B |
| China Meheco Group | 35.24B |
| Guangxi LiuYao Group | 21.15B |
| Liaoning Cheng Da | 9.21B |